Rare disease biopharmas featured prominently in the Q2 2013 financing landscape in not just venture funding, but across several financing types. These companies were involved in 15 financings (including four Series A rounds) and brought in a collective $632 million.
Rare Disease-Focused Companies Raise Plenty Of Cash In Q2 2013
SOURCES: Elsevier’s Strategic Transactions; Company web sites
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn
Tevard Biosciences CEO Daniel Fischer discusses how engineered suppressor tRNAs overcome nonsense mutations, restoring full-length protein production to treat rare genetic diseases like Dravet syndrome.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
